Indegene News and Updates

Name: Latest research reports of Indegene Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Indegene Ltd.
Rating: 3
Author: Motilal Oswal

Keep track of all breaking news on Indegene from all sources in a single place.

Indegene Ltd.

11 Aug 2026

601.50

0.22%

Indegene eyes clinical-research acquisition to widen pharma services play

Business Standard

The company is evaluating specialised CROs, data-management and patient-recruitment businesses as it looks to expand across the pharmaceutical value chain

Indegene has gained 30.08% in the last 6 Months

Indegene Ltd.

31 Jul 2026

601.50

0.22%

to see Rapid results content

Indegene Ltd.

31 Jul 2026

601.50

0.22%

Indegene Ltd. Results Earnings Call for Q1FY27

Conference Call with Indegene Ltd. Management and Analysts on Q1FY27 Performance and Outlook. Listen to the full earnings transcript.

audio

Indegene Ltd.

31 Jul 2026

601.50

0.22%

Performance in line with expectations; FY27 expected to be better than FY26

Neutral: Indegene Ltd.

Target

Motilal Oswal

Indegene’s 1QFY27 revenue rose 2.5% QoQ and 26.5% YoY to USD113m (in line with our estimate), while INR revenue grew 6.0% QoQ and 39.7% YoY to INR10.6b (MOFSL est: INR10.4b).

Indegene has gained 30.08% in the last 6 Months

Indegene Ltd.

29 Jul 2026

601.50

0.22%

Indegene: Initiating Coverage

Buy: Indegene Ltd.

IDBI Capital

market depends on pharma commercialization, medical affairs and regulatory outsourcing with an estimation at over USD 40bn by 2033, yet Indegene's FY26 revenue represents well under 0.2% of this opportunity. Rising drug development costs, patent cliffs, and increasing outsourcing...

Indegene has gained 30.08% in the last 6 Months

Indegene Ltd.

02 May 2026

601.50

0.22%

Robust growth with improving life sciences demand outlook

Buy: Indegene Ltd.

ICICI Securities Limited

Indegene showed robust revenue growth performance with broad-based traction across ECS/EMS. Issues in top client seem to have abated for now.

Indegene Ltd. has an average target of 603.33 from 3 brokers.

Indegene Ltd.

02 May 2026

601.50

0.22%

Performance in line; FY27 likely to be better than FY26

Neutral: Indegene Ltd.

Target

Motilal Oswal

Indegene’s 4QFY26 revenue rose to 6.5% QoQ to INR10b (in line with our estimate), while Ex-BioPharm revenue growth stood at 5.6%.

Indegene Ltd. has an average target of 603.33 from 3 brokers.

Indegene Ltd.

30 Apr 2026

601.50

0.22%

to see Rapid results content

Indegene Ltd.

30 Apr 2026

601.50

0.22%

Indegene Results Earnings Call for Q4FY26 & Full Year

Conference Call with Indegene Ltd. Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.

audio

Indegene Ltd.

31 Jan 2026

601.50

0.22%

Acquisition drives growth with steady organic performance

Neutral: Indegene Ltd.

Motilal Oswal

Indegene’s 3QFY26 USD revenue rose 15.1% QoQ, aided by the BioPharm acquisition, while organic USD revenue growth stood at 4% QoQ (below our estimate).